

FORM PTO-1449 (Modified)		Attorney Docket No.: 019904-000210US		Application No.: 09/244,457	
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)		Applicant: Schatzberg and Belanoff			
		Filing Date: 02/04/99		Group: 1614	
Reference Designation		U.S. PATENT DOCUMENTS			Page 1
Examiner Initial	Document No.	Date	Name	Class	Filing Date (If Appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>					
	Document No.	Date	Country	Class	Translation (Yes/No)
AA	WO 9322685	11/11/1993	PCT		
AB	WO 9408588	04/28/1994	PCT		No
AC	EP 0763541	03/19/1997	EP		Yes
AD	WO 9710827	03/27/1997	PCT		No
AE	WO 9737664	10/16/1997	PCT		
AF	WO 9826783	06/25/1998	PCT		No
AG	WO 9826785	06/25/1998	PCT		No
<b>OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
AH	Beck C.A. et al. (1993) "The Steroid Antagonist RU486 Exerts Different Effects on the Glucocorticoid and Progesterone Receptors" Department of Pathology and Program in Molecular Biology, University of Colorado Health Sciences Center (S.K.N. D.P.E.) Vol. 123, No. 2, pp. 728-740				
AI	Chrousos, G.P. et al. (1989) "Clinical Applications of RU 486, a Prototype Glucocorticoid and Progestin Antagonist." In: Baulieu, E.E. and Segal, S.J. eds. The Antiprogesterin Steroid RU 486 and Human Fertility Control. New York: Plenum Press, pp.273-284				
AJ	F. Cadepond, Ph.D. et al., (1997) "RU486 (Mifepristone): Mechanisms of Action and Clinical Uses" Anna. Rev. Med. 1997, 48:129-56				
AK	Krishnan, K.R.R. et al. (1992) "RU 486 in depression" Prog. Neuro-Psychopharmacol. & Biol. Psychiat., 16:913-920				
AL	Murphy, B.E.P. et al. (1993) "Possible Use of Glucocorticoid Receptor Antagonists in the Treatment of Major Depression: Preliminary Results Using RU 486" J. Psychiatr. Neurosci., 18:209-213				
AM	Murphy, B.E.P. s(1997) "Antiglucocorticoid therapies in major depression: A review" Psychoneuroendocrinology, 22:s125-132				
AN	Nieman, L.K. et al. (1985) "Successful treatment of Cushing's Syndrome with the Glucocorticoid Antagonist RU 486" J. Clin. Endocrinol. Metab., 61:536-540				
AO	Rothschild, A.J. et al. (1982) "The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients" Brit. J. Psychiat., 141:471-474				
AP	Rothschild, A.J. et al. (1985) "The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain" Life Sci. 36:2491-2501				
AQ	Sartor, O. et al. (1996) "Mifepristone: Treatment of Cushing's Syndrome" Clin. Obstetrics and Gynecol. 39:506-510				
AR	Schatzberg, A.F. et al. (1983) "The Dexamethasone Suppression Test: Identification of Subtypes of Depression" Am. J. Psychiat., 140:88-91				
AS	Schatzberg, A.F. et al. (1985) "A corticosteroid/dopamine hypothesis for psychotic depression and related states" J. Psychiat. Res., 19:57-64				
AT	Schatzberg, A.F. et al. (1988) "The Roles of Glucocorticoid and Dopaminergic Systems in Delusional (Psychotic) Depression" Annals N.Y. Acad. of Sci., 537: 462-471				
AU	Van der Lely, A.J. et al. (1991) "Rapid Reversal of Acute Psychosis in the Cushing Syndrome with the Cortisol-Receptor Antagonist Mifepristone (RU 486)" Ann. Intern. Med., 114:143-144				
AV	Van der Lely, A.J. (1993) Pharmacy World & Science, 15:89-90				
EXAMINER		WILLIAM R. A. JARVIS		DATE CONSIDERED 3/16/00	
		PRIMARY EXAMINER			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.